Market research
ALGEN.PA genOway S.A
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 30M
- P/E ratio
- 24.4
- Analyst target
- 6.6
- Dividend yield
- Not available
- Beta
- 0.37
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0004053510
- Market cap
- 30M
- P/E ratio
- 24.4
- Analyst target
- 6.6
- Dividend yield
- Not available
- Beta
- 0.37
About
About genOway S.A
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was incorporated in 1999 and is based in Lyon, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALGEN.PA discussion.
5 years, 5 months ago
genOway Société anonyme is currently in a long term uptrend where the price is trading 10.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Based on the above factors, genOway Société anonyme gets an overall score of 2/5.